HIV-HCV Coinfection
 

Does Coinfection with HIV Facilitate Mother-to-child and Female-to-male Transmission of HCV?
By Ronald Baker, PhD

Fifty to 90% of HIV positive individuals are reportedly coinfected with hepatitis C virus (HCV), depending on the risk group being described [1]. It is well established that HIV coinfection accelerates the progression of HCV disease. In addition, there are data to suggest that HCV coinfection accelerates the progression of HIV disease [2,3], although the study results are conflicting.

Although there is ample evidence supporting the conclusion that injection drug use is the primary mode of transmission of HCV, the cause of greater than 20% of new HCV infections cannot be accounted for [4,5].

There are some reports that sexual intercourse may transmit HCV [4, 6,7], as well as childbirth [8,9], and even casual contact among members of the same household [10]. Interestingly, HIV coinfection with HCV appears to increase the possibility of mother-to-child and female-to-male transmission of HCV. [9]. However, the evidence supporting female-to-male transmission of HCV is scant [11,12].

There are also some data suggesting that HCV replication may be directly enhanced by the presence of HIV-1 [13]. Very few studies have assessed the presence of HCV RNA in vaginal secretions.

The purpose of the current study was to analyze the presence of HCV RNA in cervicovaginal lavage (CVL) fluid from 71 women enrolled in the Women's Interagency HIV Study. Results of the study, conducted at 3 medical centers, appear in the November 1, 2005 issue of the Journal of Infectious Diseases [14].

Results

Fifty-eight of the women were HCV-HIV coinfected and 13 had HCV monoinfection.

HCV RNA was detected (by a commercial polymerase chain reaction assay) in CVL fluid from 18 (29%) of the HIV-1-infected women and from none of the HIV-1-uninfected women (P < .05).

Multivariate analysis revealed that risk factors for the presence of HCV RNA in CVL fluid were HCV viremia and HIV-1 RNA in CVL fluid.

This observation suggests local interactions between HIV-1 and HCV in the genital tract compartment.

There was no correlation between HCV RNA in CVL fluid and CD4, CD8, or CD3 cell counts, HIV-1 RNA viremia, the number of leukocytes in CVL fluid, or HIV-1 therapy.

Furthermore, in 3 of 5 analyzed patients who had a detectable CVL HCV RNA load, the researchers found viral variants differing in the 5′ untranslated region that were present neither in plasma nor in peripheral-blood mononuclear cells.

Discussion

“To our knowledge, our study is the first to demonstrate compartmentalization of HCV in the genital tracts of HCV-HIV-1 coinfected women and possible local replication in a large proportion of HCV-HIV-1 coinfected women,” write the authors.

Further, they note, “We found unique but related viral variants in the blood and genital tract compartments, suggesting that HCV may replicate locally in cells shed from the genital tract.”

These findings have important implications for both sexual and perinatal transmission of HCV.

“Findings from our study,” write the authors, suggest that “a local HCV genital tract reservoir may exist and that this may be the source of infection for those suspected to have been infected sexually.”

The mechanism by which local HIV-1 facilitates the presence of HCV in the genital tract remains unclear.

In conclusion, the authors state, “We have found that HCV RNA can be detected in almost 30% of HCV-HIV-1 coinfected women and that viral diversity does exist between local HCV and plasma HCV extracted from HCV-HIV-1 coinfected women.”

“Our findings may explain a comparatively higher rate of HCV vertical transmission by HIV-1–coinfected women reported in several studies. The relationship between HIV-1 and HCV shedding is intriguing and suggests a unique local interaction between these 2 viruses in the genital tract.”

Maternal-Child and Adolescent Center for Infectious Diseases and Virology, University of Southern California, Los Angeles; Mayo Clinic, Scottsdale, and St. Joseph's Hospital and Medical Center, Phoenix, Arizona; Medical Academy, Warsaw, Poland.

10/07/05

Source

M J Nowicki and others. Presence of Hepatitis C Virus (HCV) RNA in the Genital Tracts of HCV/HIV-1–Coinfected Women. The Journal of Infectious Diseases 192(9): 1557-1565. November 1, 2005.

References

1.       M E Eyster and others. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 6:602–610. 1993.

2.       G Greub and others. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356:1800–1805. 2000.

3.       Piroth L, Duong M, Quantin C, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 12:381–38. 1998.

4.       H Alter and others. Discovery of non-A, non-B hepatitis and identification of its etiology. Am J Med  107(Suppl):S16–S20. 1999.

5.       M J Alter and others. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–562. 1999.

6.       J G Feldman and others. Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner city women. Sex Transm Dis 27:338–42. 2000.

7.       P Halfon and others. Molecular evidence of male-to-female sexual transmission of hepatitis C virus after vaginal and anal intercourse. J Clin Microbiol 39:1204–1206. 2001.

8.       D M Gibb and others. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 356:904–907. 2000.

9.       S L Thomas and others. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viremia or human immunodeficiency virus infection. Int J Epidemiol  27:108–117. 1998.

10.    Z Ackerman and O Paltiel. Intrafamilial transmission of hepatitis C virus: a systematic review. J Viral Hepat 7:93–103. 2000.

11.    N F Hallam and others. Low risk of sexual transmission of hepatitis C virus. J Med Virol 40:251–253. 1993.

12.    R Wyld and others. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J Infect 35:163–6. 1997.

13.    M Beld and others. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 244:504–512. 1998.

14.    M J Nowicki and others. Presence of Hepatitis C Virus (HCV) RNA in the Genital Tracts of HCV/HIV-1–Coinfected Women. The Journal of Infectious Diseases 192(9): 1557-1565. November 1, 2005.


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



Index of HIV-HCV Coinfection Articles by Topic

Acute HCV in HIV Coinfection
Adherence (HCV Drugs) / Adherence
Age
ALT (alanine aminotransferase)
ALT flares
AST (aspartate aminotransferase)
Anemia (ribavirin-related)
APRICOT Trial (HAART plus Pegasys/Copegus)
Body Mass Index
CD3+, CD8+, CD4+ Cells/ Cell Count
Children and Infants
Cirrhosis / Cirrhotic Patients
Clinical Trials
Cognitive Functioning
Combination Therapy
Conferences/ Workshops on HIV-HCV Coinfection
Depression (HCV-related)
Developing Countries
Discontinuation of HAART or HCV Therapy in Coinfected Patients
Dosing (standard interferons)
Dosing (peginterferons: Pegasys or Peg Intron)
Dosing (ribavirin)
Dosing (HIV drugs)
Drug Interactions
End-of-Treatment Response (ETR)
Epidemiology
Erythropoietin
Experimental Treatments
Extrahepatic Complications
FDA-approved Anti-HCV Treatments
FDA-approved Anti-HIV Treatments
FDA-approved HIV-HCV Coinfection Treatments
Fibrosis / Fibrosis progression
Filgrastim
DNA Polymorphisms
Gay Men
Genotypes (general)
Genotypes 1 and 4
Genotypes 2 and 3
Genotypes (multiple coinfection)
Genotypes non 1,2,3,4
Growth Factors
Guidelines for Treatment of HCV
HAART
HAART and Hepatotoxicity
HAART (PI-based)
HCV Clearance (eradication)
HCV as Cofactor for HIV Disease Progression
HCV Core Antigen
HCV Disease Progression
HCV Drug-related Toxicities/Side Effects
Pegasys/ Copegus
Peg Intron / Rebetol
HCV Mortality in HCV-HIV Coinfection
HCV RNA (HCV Viral Load)
HCV-related brain damage
HCV Quantitative Assay (TRAK-C)
HCV Viral Load
Hemophilia
Hepatic Decompensation / Hepatic impairment
Hepatocellular Carcinoma (HCC)
Hepatomegaly
Histological Response (HR) Rate / Histologic Progression
HIV-HCV-HBV triple coinfection
HIV as Cofactor for HCV Disease Progression
HIV Disease Progression
HIV Drug-related Toxicities/Side Effects
HIV RNA (HIV viral load)
Immune Responses / Immune Restoration
Immune Suppression
Injection Drug Users (IDU)
Interferon (IFN): standard interferon alfa-2a (Roferon A)
Interferon (IFN): standard interferon alfa-2b (Intron A)
Interleukin-2 (IL-2)
Jaundice
Lipodystrophy in HIV-HCV Coinfection
Liver Biopsy
Liver Disorders
Liver Failure
Liver Histology
Liver Toxicity (HCV drug-related)
Liver Toxicity (HAART-related)
Liver-related Death
Liver Transplantation
Mitochondrial Toxicity
Morbidity (HCV- or HIV-related)
Non-invasive laboratory Index
Nonresponders
Ophthalmic (eye-related) Pathology from interferon Therapy
Pegasys (peginterferon alfa-2a) plus Copegus (ribavirin) Combination Therapy
Pegasys/Copegus and Intron A/ Rebetol: Toxicity / Side Effects
Peginterferon Alfa-2a
Peg Intron (peginterferon alfa-2b) plus Rebetol (ribavirin)
Peg Intron / Rebetol and Intron A / Rebetol Toxicity / Side Effects
Pharmacokinetics (HIV drugs)
Pharmacokinetics (HCV drugs)
PRESCO Trial
Prevalence of HIV-HCV Coinfection
Prevalence of HCV
Psychiatric (mental) Disorders
Quality of Life
Recurrent HCV
Reports on Conferences and Workshops
Resistance of HCV to Peginterferon /Ribavirin
Retreatment (FDA-approved) of Nonresponders w/ Pegasys/Copegus
RIBAVIC Trial (HAART plus Peg Intron/Rebetol)
Ribavirin
Ribavirin Dosing
Safety
Side Effects
Steatosis
"Stopping Rule" (discontinuation of therapy) at 12 weeks)
Substance Abuse
Survival
Sustained Virological Response (SVR) / Early Virological Response (EVR)
Test for HCV
Test for HIV
Transplantation (liver)
Treatment Guidelines
Treatment Interruptions of HAART
Treatment of HCV in HIV-HCV Coinfection: FDA-approved
Treatment of HCV in HIV-HCV Coinfection: Experimental
Viral Kinetics (HCV) / Early HCV Kinetics / HCV Decay
Weight-based Dosing
Weight-based Dosing of Peg Intron and Rebetol
Women
Youth

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HIV AND AIDS
| HEPATITIS B | HEPATITIS C | HIV / HBV CO-INFECTION | HIV / HCV CO-INFECTION | HEALTH | TESTS |
INTERNET CONFERENCE REPORTS
|
LINKS | ABOUT US | CONTACT US